GSK selects Witty as next CEO

Share this article:

GlaxoSmithKline (GSK) has tapped Englishman Andrew Witty to succeed Jean Pierre Garnier as CEO in May.

At age 43, Witty will become the youngest–ever leader of Europe's largest drug maker at a time when the company is seeking to reinvigorate its sales growth.

Witty has worked for the UK-based GSK in the US, Asia and Africa and became president of European operations in 2003.

Witty joined GSK in 1985 in the UK where he held positions as director of pharmacy and distribution and international product manager.

Outside the UK, he was director for south and east Africa and marketing manager for GSK's US unit before moving to Singapore as an Asian SVP.

Garnier, who turns 60 at the end of October, joined SmithKline Beecham in 1990 as president of its North American pharmaceuticals division. He was named CEO in 2000.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.